Yang Jin, Cai Bingcui, Glencer Patrick, Li Zhiqing, Zhang Xiaomin, Li Xiaorong
Tianjin Medical University Eye Hospital, Tianjin 300384, China.
Nova Southeastern College of Optometry, Fort Lauderdale, FL 33314, USA.
Stem Cells Int. 2016;2016:2850873. doi: 10.1155/2016/2850873. Epub 2016 Jan 5.
The retina, which is composed of multiple layers of differing cell types, has been considered the first choice for gene therapy, disease modeling, and stem cell-derived retinal cell transplant therapy. Because of its special characteristics, the retina, located in the posterior part of the eye, can be well observed directly after gene therapy or transplantation. The blood-retinal barrier is part of a specialized ocular microenvironment that is immune privileged. This protects transplanted cells and tissue. Having two eyes makes perfect natural control possible after a single eye receives gene or stem cell therapy. For this reason, research about exploring retinal diseases' underlying molecular mechanisms and potential therapeutic approach using stem cell technique has been developing rapidly. This review is to present an up-to-date summary of the iPSC's sources, variations, differentiation methods, and the wide-ranging application of iPSCs-RPCS or iPSCs-RPE on retinal disease modeling, diagnostics, and therapeutics.
视网膜由多层不同类型的细胞组成,一直被视为基因治疗、疾病建模和干细胞衍生视网膜细胞移植治疗的首选。由于其特殊特性,位于眼球后部的视网膜在基因治疗或移植后可直接被很好地观察到。血视网膜屏障是免疫特权的特殊眼部微环境的一部分。这保护了移植的细胞和组织。拥有双眼使得在单眼接受基因或干细胞治疗后进行完美的自然对照成为可能。因此,利用干细胞技术探索视网膜疾病潜在分子机制和潜在治疗方法的研究发展迅速。本综述旨在对诱导多能干细胞(iPSC)的来源、变体、分化方法以及iPSC来源的视网膜色素上皮细胞(iPSCs-RPE)或iPSC来源的视网膜祖细胞(iPSCs-RPC)在视网膜疾病建模、诊断和治疗方面的广泛应用进行最新总结。